

Daniel O. Claassen, M.D. M.S.**August 2020**

Associate Professor of Neurology
Vanderbilt University Medical Center
Department of Neurology
1500 21st Ave. S.
Suite 1532, Room 1213
Nashville TN 37212
615.936.1007(office)
615.343.3946 (fax)
daniel.claassen@vumc.org

Education

- University of Georgia (Athens, GA), Bachelor of Music, cum laude with honors (8/95-5/99)
- University of Georgia (Athens, GA), Masters of Science, Nutrition and Biochemistry (7/99-8/01)
- The Medical College of Georgia (Augusta, GA), Medical Doctorate, (8/01-5/05)
- University of Virginia, Masters of Science, Clinical Research, (7/09-6/11)

Postgraduate training

- Mayo Clinic, Rochester MN, Preliminary Medicine Resident (6/05-6/06)
- Mayo Clinic, Rochester MN, Neurology Resident (7/06-6/09)
- University of Virginia, Neurodegeneration, Mentor: G. Frederick Wooten (7/09-6/11)

Licensure and Certification:

- State of Minnesota (2006-2008)
- Commonwealth of Tennessee, License number: 47418 (2011-present)
- Diplomat of the American Board of Psychiatry and Neurology (2010-present)
- UCNS Behavioral Neurology and Neuropsychiatry (2012-present)

Board Certifications

1. USMLE Step 1 2003
2. USMLE Step 2 CK 2004
3. USMLE Step 2 CS 2005
4. USMLE Step 3 2006
5. American Board of Neurology and Psychology, 2009
6. Behavioral Neurology and Neuropsychiatry (United Council for Neurologic Subspecialties), 2012

Academic Appointments:

- Instructor of Neurology, Mayo Clinic, Rochester MN, (7/08-6/09)
- Instructor of Neurology, University of Virginia, Charlottesville, VA (7/09-6/11)
- Assistant Professor of Neurology, Vanderbilt University, (7/11- 2/17)
- Associate Professor of Neurology, with tenure, Vanderbilt University Medical Center (3/17-present)

Hospital Appointments

- Mayo Clinic, Rochester MN, Instructor of Neurology (7/08-6/09)
- University of Virginia Health System, Clinical Instructor of Neurology (7/09-6/11)
- Vanderbilt University, Assistant Professor of Neurology (7/11- 2/17)
- Vanderbilt University Medical Center, Associate Professor of Neurology (3/17- present)
- Chief, Behavioral and Cognitive Neurology, Vanderbilt University Medical Center (07-2018-present)

Professional Organizations:

- American Academy of Neurology
- American Neurological Association
- Movement Disorder Society
- Huntington's Study Group
- Society for Neuroscience
- Southern Clinical Neurological Society

Professional Activities:

Intramural

- Director, Cognitive and Behavioral Neurology Fellowship (2014- present)
- Director, Huntington Disease Center of Excellence (2015- present)
- Member, Neurology Residency Program Evaluation Committee (2016-present)
- Member, Lab formulary committee (2017-present)
- Division Chief, Behavior and Cognitive Neurology, (2018-present)

Extramural

- American Academy of Neurology: Distance Learning Subcommittee. (2009 - 2012)
- Neurology on the Hill, Washington DC (2008 -2012)
- Huntington's Study Group. Education Committee (2016 - 2018)
- Huntington's Study Group. Continuing Medical Education steering committee (2016 - 2018)
- Movement Disorders Society, Evidence Based Medicine Committee, Huntington's Disease Subgroup (2016 - 2018)
- Huntington's Study Group. Credentials Committee (2014 - present)
- Southern Clinical Neurological Society: Scientific Programing Chair (2016 - present)
- ENROLL-HD Care Improvement Committee (2016 - present)
- ENROLL-HD Scientific Oversight Committee (2018 - present)
- Editor, *HD Insights* (2018 - present)
- Associate Editor, *Mayo Clinic Proceedings* (2019 - present)

Clinician Investigator Roles

- Principle Investigator: Biomarkers for the progression if Multiple Systems Atrophy (bioMUSE) (2020-present)
- Co-Principle Investigator: RECLAIM-DCP. A global multicenter study determining the efficacy of tetrabenazine for the treatment of dyskinetic cerebral palsy. (2019-present)

- Coordinating Investigator: PRECISION-HD: an allele specific antisense oligomer for disease modification in Huntington Disease (2018-present)
- Coordinating Investigator: ARTISTS A global multicenter study assessing the treatment of Tourette Syndrome. (2016-2020)

Ad Hoc Reviews:

(1) Selected Journals (more than 3 reviews per journal over the last 5 years)

- *Annals of Neurology*
- *Brain*
- *Brain Research*
- *Cortex*
- *Dementia and Geriatric Cognitive Disorders*
- *JAMA Neurology*
- *Journal of Neurology, Neurosurgery, and Psychiatry*
- *Journal of Nuclear Medicine*
- *Movement Disorders*
- *Neurodegenerative Diseases*
- *Neurology*
- *Neuroimage*
- *Neuroimage Clinical*
- *Neuropsychologia*
- *Journal of Parkinson's Disease*
- *Journal of Huntington's Disease*
- *Parkinson's disease and related disorders*

(2) Grant Review

- *Israel Science Foundation (2012-2013)*
- *Neurological Foundation of New Zealand (2013-2016)*
- *American Academy of Neurology, Clinical Research Training grants (2013-present)*
- *Medical Research Council, United Kingdom (2016--present)*
- *Brain Disorders & Clinical Neuroscience, ad hoc member (2016-present)*
- *Clinical Neuroscience and Neurodegeneration Study Section, ad hoc member (2016-2020)*
- *Clinical Neuroscience and Neurodegeneration Study Section, appointed member (2020-2026)*

Teaching Activities:

Invited Lectures

“Alterations to Risk and Reward in Parkinson Disease” March 17th, 2011. Department of Neurology, Georgia Health Sciences University, Augusta, GA. Presentation of research regarding medication-influenced cognitive processes in Parkinson Disease patients with Impulsive Compulsive Behaviors.

“Dopamine Effects on Ventral Striatal Processes” April 29th, 2011. Department of Public Health Sciences, University of Virginia, Charlottesville VA. Presentation of data regarding Parkinson Disease patients with Impulsive Compulsive Behaviors.

“Elucidating Fronto-striatal changes in Parkinson Disease Patients” May 27th, 2011. Department of Neurology, Georgetown University, Washington DC. Presentation of research regarding action-control processes in Parkinson Disease patients.

“Impulsive Compulsive Behaviors in Parkinson Disease” January 24th, 2012. Department of Psychiatry, University of Virginia, Charlottesville VA. Presentation of research regarding clinical and cognitive characterization of patients with Impulsive Compulsive Behaviors and Parkinson Disease.

“Imaging Behavioral Problems in Parkinson’s Disease” Vanderbilt University Imaging Institute Seminar, June 2013.

“Updates in the treatment of Dementia with Lewy Bodies” Contemporary Clinical Neurology Symposium, Hilton Head, SC, July 2013

“Opportunities to Participate in Parkinson’s Disease Research” The Michael J. Fox Foundation, Southeast Clinical Trials Fair, February 2014.

"Huntington’s Disease: Therapy for Chorea in the Long Term Care Setting" American Medical Directors Association, (AMDA). Nashville TN, February 2014.

“Impulsive and Compulsive Disorders in Parkinson’s Disease” Grand Rounds. Department of Neurology University of Alabama at Birmingham, Birmingham AL, April 2014

“Cognition and Huntington’s Disease ” Huntington’s Disease Society of America, 29th Annual Convention” Louisville, KY, June 2014.

“Cognition and Huntington’s Disease – Managing Cognitive Problems” Huntington’s Disease Society of America, 29th Annual Convention. Louisville, KY, June 2014.

“Cortical changes with Parkinson’s Disease: getting older, and longer duration” Movement Disorders Grand Rounds, Department of Neurology, University of Florida, Gainesville FL, February 2015

“Update on Huntington’s Disease and Emerging Therapies” Contemporary Clinical Neurology Symposium, Hilton Head, SC, July 2015

“Impulsive and Compulsive Behaviors in Parkinson’s Disease.” Grand Rounds. Department of Psychiatry, Vanderbilt University, Nashville, TN, October, 2015

“Impulsive and Compulsive Behaviors in Parkinson’s Disease.” Grand Rounds. Department of Neurology, University of Utah, Salt Lake City, UT, November, 2015

“Multiple Systems Atrophy, and Treatment for Autonomic Disorders” Southern Clinical Neurology, West Palm Beach, January 2016

“Impulsive and Compulsive Behaviors in Parkinson’s Disease.” Grand Rounds. Department of Neurology, University of Tennessee, Memphis, TN April 1st, 2016

“Behavioral changes in Parkinson’s Disease” Grand Rounds. Department of Neurology, Mayo Clinic, Jacksonville, TN November 30th, 2017

“Insights into Impulsivity” Neurology Seminar. Department of Neurology, Columbia University, New York, NY March 27th, 2018

“Problem behaviors and their treatment Huntington’s Disease” Huntington’s Disease Society of America, Annual Convention” Boston, MA, June 27th, 2019.

“Advances in Multiple Systems Atrophy clinical research” Multiple Systems Atrophy Patient and Family Annual conference, Orlando FL, September 12th, 2019

“Dopamine, the Reward Circuit, and Impulsive behavior in Parkinson Disease” Grand Rounds, Department of Neurology, Yale, New Haven, October 18th, 2019

“Huntington’s Disease Insights of the year.” Huntington Study Group Annual meeting, Sacramento, CA November 3rd, 2019

Medical School Teaching

“Parkinsonism” November, 2011, 2013. Department of Neurology—Medical Student Lecture Series Vanderbilt University

“Age Associated Memory Impairment” Brain, Behavior, and Movement (BBM), November 26th, 2013

“Impulse Control Disorders” Brain, Behavior, and Movement (BBM), December 11th, 2013

“Non-motor aspects of Parkinson’s Disease” Brain, Behavior, and Movement (BBM). June 5th, 2014

"Delirium, dementia, and amnesic syndromes", Brain, Behavior, and Movement (BBM), June 16th, 2014

“Memory and Dementia” Brain, Behavior, and Movement (BBM) June 10th, 2015.

Graduate School Teaching

“Mesocorticolimbic (dys) function in Parkinson disease” November, 2012, 2014, 2016. Graduate Course: NURO 366. Seminar in Neuroscience Vanderbilt University. Lecture outlining approaches to understanding mesocorticolimbic function in Parkinson disease.

“Overview of the Cerebral Cortex” 2015, 2017. Graduate Course: NURO345 Seminar in Neuroscience Vanderbilt University.

“Dementia and the differential diagnosis” 2016, 2017, 2018 Graduate seminar: Neurobiology of Disease, Vanderbilt University

“Cognitive changes in Parkinson’s Disease and Dementia with Lewy Bodies” 2017, 2018, 2019 Graduate seminar: Neurobiology of Disease, Vanderbilt University

Resident Teaching

“Approach to the atypical parkinsonian patient” September, 2011, 2013, 2015, 2017, 2019. Department of Neurology, Vanderbilt University. Lecture guided to Residents and Fellows as part of the Movement Disorder Lecture Series.

“Diagnostic Aids in the Dementia Work-up” March, 2012, 2014, 2016, 2018 Department of Neurology, Vanderbilt University. Grand Rounds Review biomarkers, clinical approach, and differential diagnosis of common memory complaints.

“Essentials of the Proper Diagnosis of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia.” Monday Noon Educational Conference Series, Vanderbilt University Medical Center, Nashville, TN, April, 2014, 2015, 2016, 2017, 2019.

“Approach to Dementia and Delirium” Internal Medicine Residency Lecture Series. June, 2014, 2015, 2016, 2017, 2018.

“Motor and Gait Changes in Aging” Vanderbilt Geriatric Psychiatry Lecture, November 2014, 2015, 2016, 2017, 2018

Clinical Teaching

Medical Student 3rd Year Subspecialty Neurology Rotation: Medical Students learn the approach to evaluating patients with disorders affecting cognition, behavior, and memory. Emphasis is made on application of bedside cognitive testing and development of a differential diagnosis. (2012-2018)

Neurology Resident Subspecialty Series: Residents rotate through the Cognitive and Behavioral Neurology Subspecialty Clinic once a week, for 1 month. Emphasis is made on developing a diagnostic plan, integrating and interpreting Neuropsychology assessment, learning the utility of neuroimaging and genetic work-up, and developing treatment plans. (2013-2018)

Research Supervision (Designated as content area mentor or primary mentor)

“Mechanism of Neuronal Manganese transport and toxicity”
Graduate Student: Kevin Kumar MD, PhD (2012-2014)
Role: Content area mentor, Neuroscience PhD Thesis Committee
Current position: Neurosurgery resident, Stanford University.

“Amyloid and FDG PET Imaging in Alzheimer’s Disease”
Postdoctoral Student: Sepideh Shokouhi PhD (2012-2014)
Role: Content area mentor
Current Position: Research Assistant Professor, Vanderbilt University Medical Center

“Reward learning and perseveration is influenced by Dopamine therapy in Parkinson Disease”
Undergraduate Student: Lydia Qualis (2011-2012)
Role: Primary mentor, Vanderbilt Honors Thesis Supervisor
Current Position: Neuropsychology graduate student, University of Mississippi

“Imaging Structure and Function in Parkinson’s and Alzheimer Disease”
Postdoctoral Student: Swati Rane PhD (2013-2015)

Role: Content area and primary mentor
Current Position: Research Assistant Professor, University of Washington

“ApoE and Alzheimer Disease” HHMI/VUMC Certificate Program in Molecular Medicine
Postdoctoral Student: Yuanli Song PhD (2013-2014)
Role: Content area mentor
Current Position: Staff Scientist, Astra Zeneca

“Assessments of motor and cognitive impulsivity”
Postdoctoral student: Nelleke van Wouwe, PhD (2012-2016)
Role: Primary mentor
Current position: Assistant Professor, Neurology, University of Louisville

“Norepinephrine Effects on Cognition in Parkinson’s Disease”
Clinical Fellow: Katherine McDonnell, MD (2014-2017)
Role: Primary mentor: Cognitive and Behavioral Fellowship Director
Current position: Assistant Professor of Neurology, Clinical-educator track, Vanderbilt University Medical Center

“White matter imaging in aging and degeneration”
Mentee: Meher Juttukonda, PhD (2015-present)
Role: Content area mentor
Current position: Postdoctoral student, Vanderbilt University Medical Center

“Biological determinants of tremor manifestation”
Mentee: Giulia Franco, MD (2016-2017)
Role: Primary mentor: clinical research fellowship
Current position: Faculty Neurologist, Milan, Italy

“Advanced imaging methods in neurodegeneration: assessing disease related changes to melanin, magnetization transfer, and neurochemical function.”
Mentee: Paula Trujillo, PhD (2016 – present)
Role: Primary research mentor
Current position: Postdoctoral student, Vanderbilt University Medical Center

“Functional Imaging in Parkinson’s disease”
Graduate Student: Kalen Petersen (2016-2019)
Role: Primary mentor
Current position: Postdoctoral Fellow, Vanderbilt University Medical Center

“Advanced Statistical Methods for the study of Neurodegeneration”
Graduate Student Mentee: Allison Hainline (2016-2019)
Role: Content area mentor
Current position: PhD candidate (Biostatistics), Vanderbilt University

“Discourse and motor speech changes in patients with Huntington’s Disease”
Graduate Student: Sarah Diel, MS CF-SLP (2016-present)
Role: Content area mentor
Current position: PhD candidate (Speech and language pathology), Vanderbilt University Medical Center

“Improving methods for magnetic resonance imaging segmentation”

Graduate Student: Camilo Bermudez Noguera, BS (2016-present)

Role: Content area mentor

Current position: MD/ PhD candidate (Biomedical engineering)

“Identifying and treating neuropsychiatric symptoms in Huntington’s Disease”

Mentee: Jessie Sellers, NP (2016-2019)

Role: Primary mentor

Current position: Postdoctoral Fellow, Vanderbilt University

“Manganese biology in Huntington’s Disease”

Student: Miles Bryan (2017- 2019)

Role: F31 co-mentor (mentor), Neuroscience PhD Thesis Committee

Current position: Postdoctoral fellow, University of North Carolina

“Neural networks, psychosis, and social behavior in dementing disorders”

Junior Faculty Mentee: Ryan Darby (2017-present)

Role: Primary research mentor

Current position: Assistant Professor of Neurology (tenure track), Vanderbilt University Medical Center

“Risk taking behavior in Huntington Disease”

Junior faculty: Katherine McDonnell, MD (2018-present)

Role: Primary mentor:

Current position: Assistant Professor of Neurology, Clinical-educator track, Vanderbilt University Medical Center

“Biomarkers of sensory processing in Tourette Syndrome”

Junior faculty: David Issacs, MD (2019-present)

Role: Primary mentor

Current position: Assistant Professor of Neurology, Clinical-educator track, Vanderbilt University Medical Center

Research Funding:

Active Grants

1R01AG062574 (Claassen, Donahue, mPI)

04/01/2020 - 03/31/2025

National Institute on Aging

\$600,651

Quantitative Imaging of Brain Glymphatic Function in Humans

The goal of this work is to apply novel imaging approaches to quantify relationships between physiological hallmarks of Alzheimer’s disease related dementia (ADRD) and central nervous system (CNS) lymphatic function in humans.

Role: co- Principal Investigator

W81XWH-19-1-0812 Claassen (PI)

10/01/2019 – 09/30/2022

Department of Defense

\$1,500,000.00

Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson’s Disease

This department of defense grant assesses the role of the glymphatic system, a recently-discovered novel waste clearance pathway, in patients with Parkinson’s Disease (PD), to understand whether improvements in motor and cognitive function observed following exercise can be attributed to this system.

Role: Principal Investigator

Griffin Foundation (PI: Claassen, DO) 07/01//2018-06/30/2020
Griffin Foundation \$350,000.00
Engaging children in Huntington's disease families
This study assesses how children of HD families manage stress, the fear of HD, and interact with their parents. It focuses on cognitive and behavioral mechanisms of resilience that predict function.

R01 NS097783 (PI: Claassen, DO) 08/01/2016 – 05/31/2021
NIH/NINDS \$451,110.00
Biological Determinants of Impulsivity in Parkinson's Disease
The work assesses the biophysical, physiological and molecular relationships determining susceptibility to medication-induced behavioral changes in PD. Completion of this study will provide the basis for a novel cognitive and imaging approach that will ultimately improve the quality and care of PD patients.
Role: PI

VUMC74378 (PI: Claassen, DO) 05/15/2019-06/15/2021
Huntington Study Group \$172,604.00
KINECT-HD
The primary objective of this study is to assess the efficacy of valbenazine on the treatment of chorea in Huntington disease. The investigator is the Co-PI of a global study, with 46 sites.
Role: co-PI

VUMC41577 (PI: Claassen, DO) 04/11/2014 – 05/01/2022
CHDI Foundation \$627,500.00
Enroll-HD: A Prospective Registry Study in a Global Huntington Disease (HD) Cohort
The primary objective of Enroll-HD is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic characteristics) and biological specimens (blood) from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g., spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation). Enroll-HD is conceived as a broad-based and long-term project to maximize the efficiencies of non-clinical research and participation in clinical research. With over 200 sites in roughly 30 countries, Enroll HD will be the largest database available for HD researchers.
Role: Site Investigator

HD Center of Excellence (PI: Claassen, DO) 01/01/16 – 12/31/22
Huntington's Disease Society of America \$80,000.00
Level 1 Center of Excellence grant to promote the establishment of an interdisciplinary care model for patients with Huntington's Disease.
Role: PI

VUMC75461 (PI: Claassen, DO) 10/01/2019-09/30/2021
Alterity Therapeutics \$450,000.00
bioMUSE, a longitudinal study assessing the natural history of possible Multiple Systems Atrophy.
The Major goals of this study are to develop clinical, biofluid, and imaging biomarkers of disease progression in patients with possible MSA.
Role: PI

Current Clinical Trials

VUMC221011 (Site Investigator: Claassen, DO) 10/01/2019- ongoing
Genentech/Roche \$2,439,621.70

A Phase 3, multi-center, randomized, double-blind, placebo controlled study in subjects manifest Huntington disease to assess the efficacy of BN40955 on reducing disease progression.

Role: Site Investigator

VUMC55170 (Site Investigator: Claassen, DO)

10/01/2015 – ongoing

Vaccinex

\$1,220,000.00

A Phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with late prodromal and early manifest Huntington disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503

Role: Site Investigator

VUMC59776 (Site Investigator: Claassen, DO)

12/01/2016 - 11/22/2020

AbbVie

\$3,282,800.00

AbbVie M15-562, M15-563

The Major Goals of this project are to assess the impact of the investigational anti-tau antibody on symptom progression in Progressive Supranuclear Palsy.

Role: Site Investigator

VUMC61850 (Site Investigator: Claassen, DO)

05/21/2018-02/07/2020

Wave Life Science

\$375,450.00

Treating Single Nucleotide Polymorphisms rs362307 (T/C) and rs362331(T/C) in Patients with Huntington's Disease, using an antisenseoligomer approach

The Major Goals of this project are to determine the prevalence of the common polymorphisms in HD patients, and to perform a phase I study of assess the safety, tolerability, pharmacokinetics of the investigational compound in early manifest Huntington disease patients

Role: Site Investigator

VUMC61125 (Site Investigator: Claassen, DO)

05/21/2018-02/07/2020

Wave Life Science

\$63,953.00

WAVE Huntington's Disease Clinical Protocol Development

The Major Goals of this project are to develop a protocol for Antisense Oligonucleotide treatments for HD patients using an investigational ASO compound.

Role: Scientific Advisory Committee

Completed Funding

K23 NS080988 (PI: Claassen, DO)

09/01/2013 – 08/31/2018

NIH/NIINDS

\$186,000.00

Dopamine Effects on Mesocorticolimbic Function in Parkinson Disease.

The specific aims of the proposal are: (1) to characterize the elements of reward-motivated decision-making that underlie Impulsive Compulsive Behaviors in Parkinson Disease patients, and (2) to examine D2-like receptors in Parkinson Disease patients with and without Impulsive Compulsive Behaviors.

Role: PI

VUMC 54580 (PI: McDonnel, KE)

07/01/2016 – 06/30/2018

Lundbeck Foundation

\$150,000.00

Parkinson's Disease patients suffer from early and clinically significant cognitive impairment. This study tests the hypothesis that noradrenergic therapy, namely Droxidopa, can improve action control and motor inhibition. We will conduct an open-label therapeutic intervention using Droxidopa, and evaluate response using functional MRI and cognitive neuroscience outcomes of motor control.

Role: Co-Investigator

VUMC76986 (Site Investigator: Claassen, DO)	08/01/2018-10/01/2019
Cerecor	\$52,617.00
<i>Phase I study of CERC-301, an NMDA receptor antagonist, being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in Parkinson's Disease.</i>	
CERC-301 is an orally available, NR2B-specific, NMDA receptor antagonist being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). NMDA receptor overactivation is associated with many neurodegenerative diseases, including Parkinson's disease.	
VUMC60500 (Site Investigator: Claassen, DO)	03/13/2017 - 03/12/2018
Avid Radiopharmaceuticals, Inc.	\$169,186.00
<i>A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology</i>	
The Major Goals of this project are to assess the correspondence of tau tracer with autopsy findings.	
Role: Site Investigator	
VUMC57713 (PI: Claassen, DO)	11/01/2014 – 11/01/2017
Biomarkers Across Neurodegenerative Disease	\$140,000.00
<i>Cortical and functional distinctions in Alzheimer's and Parkinson's Disease</i>	
The overall goal of this work is to integrate MRI data from ADNI and PPMI cohorts to test fundamental hypotheses about Alzheimer's disease (AD) and Parkinson's disease (PD) pathology. To accomplish this, we will apply advanced imaging computational methods to compare tissue atrophy and functional deficits with alpha synuclein (a-SYN) concentration and APOE status in patients with early-stage AD and PD.	
Role: PI	
VUMC61124 (Site Investigator: Claassen, DO)	06/07/2017 - 06/06/2018
Bristol-Myers Squibb Company	\$474,772.00
<i>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS compound.</i>	
The Major Goals of this project are to assess the impact of the investigational anti-tau antibody on symptom progression in Progressive Supranuclear Palsy.	
Role: Site Investigator	
VUMC42856 (Site Investigator: Claassen, DO)	05/01/2014 – 08/31/2015
Auspex Pharmaceuticals	\$127,629.00
<i>A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease</i>	
Role: Site Investigator	
VUMC42856 (Site Investigator: Claassen, DO)	05/01/2014 – 05/01/2017
Auspex Pharmaceuticals	\$278,800.00
<i>An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease</i>	
Role: Site Investigator	
VUMC55065 (Site Investigator: Claassen, DO)	08/01/2015 – 10/05/2016
C2N Diagnostics	\$277,510.00
<i>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy</i>	
Role: Site Investigator	
Vanderbilt Physician Scientist Development (PI: Claassen, DO)	07/01/2012 – 09/01/2013

Dopamine Effects on Mesocorticolimbic Function in Parkinson Disease \$100,000.00

Role: PI

VUMC40270 (Site Investigator: Claassen, DO)

04/01/2013 – 06/30/2014

Teva Neuroscience

\$69,992.00

A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients with Parkinson's Disease.

Role: Site Investigator

1S10OD023543-01 (PI: Manning)

04/11/2017 - 04/10/2018

NIH/OD

\$359,000.00

Radiochemistry Equipment for Molecular Imaging Tracer Production

The Major Goals of this project are to purchase a cyclotron to enhance ligand production for PET studies in neurologic disorders.

Role: Sub-Investigator

VUMC (PI: Hedera)

07/01/2016 – 12/31/2017

Massachusetts General Hospital

\$29,928.00

An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington Disease (HD)

Role: Sub-Investigator

Clinical Research Training Fellowship (PI: Claassen)

07/01/2009 – 06/30/2011

American Academy of Neurology

\$110,000.00

Impulse Control Disorders and Parkinson's Disease: the effect of dopamine therapy on Decision-Making and Response Inhibition

This study examined the role of Dopamine Agonists on risk taking, reward learning, motor impulsivity, and inhibitory control in Parkinson Disease patients with and without Impulse Control Disorder.

Role: PI

Collaboration Development Award (PI: Claassen)

06/01/2010-07/01/2010

British Council

\$7,000.00

Motor Timing in Parkinson Disease

This collaboration evaluated alterations to motor timing in Parkinson Disease. Using the paced finger-tapping task, the study showed that PD patients distinguish themselves from non-PD patients when tapping at faster tempos, and focused on medication effects on performance.

Role: PI

Tourette Syndrome Association (Co-PI Wylie SA, Claassen DO)

07/01/2009 – 06/30/2011

TSA Foundation

\$40,000.00

Deficits and Temporal Dynamics of Inhibitory Control over Voluntary and Involuntary Actions in Tourette Syndrome.

Since it is well known that Tourettes syndrome and chronic motor tic disorder patients have difficulties with controlling an urge to make a movement, this study focused on identifying inhibitory control processes in patients with motor tics, and also extended the work to vocal inhibitory function in vocal tics.

Role:Co-PI

Mayo Clinic Small Grants (PI: Claassen)

07/01/2007 – 06/30/2009

Mayo Clinic Foundation

\$20,000.00

Clinical Utility of (11c) - PIB Imaging in Patients with Autonomic Dysfunction, REM Behavior Disorder, and Parkinsonism: Distinguishing Lewy Body Dementia From Multiple System Atrophy.

In this study, patients differentiated by Multiple Systems Atrophy and Diffuse Lewy Body Disease were prospectively identified with similar sleep, autonomic, and movement disorder symptoms, and then assessed using both glucose metabolism and amyloid imaging PET.

Role: PI

American Parkinson's Disease Association (PI: Claassen) 12/01/2009- 06/30/2011
APDA Foundation \$3,000.00
Rhythm in Parkinson's: perception and production deficits
Role: PI

National Institutes of Health (NIH) 08/01/2011-07/31/2015
Clinical Loan Repayment Program (LRP) National Institute on Aging. \$150,000.00

Articles in Refereed Journals:

1. Everts HB, Claassen DO, Hermoyian CL, Berdanier CD. Nutrient-gene interactions: dietary vitamin A and mitochondrial gene expression. *IUBMB Life*. 2002 Jun;53(6):295-301. PMID: 12625368
2. Claassen DO, Batsis JA, Orenstein R. Proteus mirabilis: a rare cause of infectious endocarditis. *Scand J Infect Dis*. 2007;39(4):373-5. PMID: 17454908
3. Zubkov A, Claassen DO, Rabinstein AA. Warfarin-associated intraventricular hemorrhage. *Neurol Res*. 2007 Oct;29(7):661-3. PMID: 18173903
4. Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA. Frontotemporal dementia mimicking dementia with Lewy bodies. *Cogn Behav Neurol*. 2008 Sep;21(3):157-63. PMID: 18797258
5. Claassen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. *Arch Neurol*. 2008 Oct;65(10):1313-8. PMID: 18852344
6. Zubkov Mandrekar JN, Claassen DO, Manno EM, Wijdicks EF, Rabinstein AA. Predictors of outcome in warfarin-related intracerebral hemorrhage. *Archives of Neurology*. AY, 2008 Oct; 65 (10): 1320-5 PMID: 18852345
7. Claassen DO, Rao SC. Locked-in or comatose? Clinical dilemma in acute pontine infarct. *Mayo Clin Proc*. 2008 Nov;83(11):1197. PMID: 18990316
8. Drubach DA, Claassen DO. Perception and the awareness of God: the importance of neuronal habituation in the context of the Jewish and Christian faiths. *J Relig Health*. 2008 Dec;47(4):541-8. PMID: 19093680
9. Claassen DO, Josephs KA. Pramipexole induced compulsive behaviors abate after initiation of rotigotine. *Mov Disord*. 2009 May 15;24(7):1090-1 PMID: 19306291
10. Fugate JE, Smith JH, Claassen DO. Bilateral cochlear enhancement in Cogan syndrome. *Neurology*. 2009 Jul 7;73(1):75. PMID: 19564589
11. Claassen DO, Boes CJ. Rosenow's rabbits and postencephalitic parkinsonism. *Neurology*. 2009 Oct 13;73(15):1240-1. PMID: 19822874

12. Smith JH, Fugate JE, Claassen DO. Pearls & Oysters: the orbital bruit: a poor man's angiogram. *Neurology*. 2009 Oct 20;73(16):e81-2. PMID: 19841375
13. Claassen DO, Josephs KA, Peller PJ. The stripe of primary lateral sclerosis: focal primary motor cortex hypometabolism seen on fluorodeoxyglucose F18 positron emission tomography. *Arch Neurol*. 2010 Jan;67(1):122-5. PMID: 20065142
14. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. *Mayo Clin Proc*. 2010 May;85(5):427-32. PMID: 20435835
15. Josephs KA, Duffy JR, Fossett TR, Strand EA, Claassen DO, Whitwell JL, Peller PJ. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. *Arch Neurol*. 2010 May;67(5):596-605. PMID: 20457960
16. Fugate JE, Rabinstein AA, Claassen DO, White RD, Wijidicks EF. The FOUR score predicts outcome in patients after cardiac arrest. *Neurocrit Care*. 2010 Oct;13(2):205-10. PMID: 20645026
17. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. *Neurology*. 2010 Aug 10;75(6):494-9. Epub 2010 Jul 28. PMID: 20668263
18. Fugate JE, Wijidicks EF, Mandrekar J, Claassen DO, Manno EM, White RD, Bell MR, Rabinstein AA. Predictors of neurologic outcome in hypothermia after cardiac arrest. *Ann Neurol*. 2010 Dec;68(6):907-14. PMID: 21061401
19. Claassen DO, Lowe VJ, Peller PJ, Petersen RC, Josephs KA. Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. *Parkinsonism Relat Disord*. 2011 Mar;17(3):160-5. Epub 2010 Dec 31 PMID: 21195652
20. Claassen DO, van den Wildenberg WP, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, Wylie SA. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. *Behav Neurosci*. 2011 Aug;125(4):492-500. PMID: 21604834
21. Jones CR, Claassen DO, Yu M, Spies JR, Malone T, Dirnberger G, Jahanshahi M, Kubovy M. Modeling accuracy and variability of motor timing in treated and untreated Parkinson's disease and healthy controls. *Front Integr Neurosci*. 2011;5:81. Epub 2011 Dec 23. PMID: 22207839
22. Wylie SA, Claassen DO, Huizenga HM, Schewel KD, Ridderinkhof KR, Bashore TR, van den Wildenberg WP. Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. *J Cogn Neurosci*. 2012 Aug;24(8):1709-24. doi: 10.1162/jocn_a_00241. Epub 2012 May 9. PMID: 22571461
23. Lehman VT, Carter RE, Claassen DO, Murphy RC, Lowe V, Petersen RC, Peller PJ. Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease. *Clin Nucl Med*. 2012 Aug;37(8):721-6. doi: 10.1097/RLU.0b013e3182478d89. PMID: 22785496
24. Wylie SA, van den Wildenberg W, Ridderinkhof KR, Claassen DO, Wooten GF, Manning CA. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. *J*

- Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1149-54. doi: 10.1136/jnnp-2012-303056. Epub 2012 Aug 23. PMID: 22917670
25. Claassen DO, Jones CR, Yu M, Dirnberger G, Malone T, Parkinson M, Giunti P, Kubovy M, Jahanshahi M. Deciphering the impact of cerebellar and basal ganglia dysfunction in accuracy and variability of motor timing. *Neuropsychologia*. 2012 Oct 16. doi:pii: S0028-3932(12)00390-9. 10.1016/j.neuropsychologia.2012.09.018. [Epub ahead of print] PMID: 23084982
 26. Wylie SA, Claassen DO, van den Wildenberg W, Ridderinkhof KR. Impaired Inhibition of Prepotent Motor Actions in Tourette's Syndrome. *Journal of Psychiatry and Neuroscience J Psychiatry Neurosci*. 2013 Jul 2;38(4):120138. doi: 10.1503/jpn.120138. PMID: 23820185
 27. Fugate JE, Moore SA, Knopman DS, Claassen DO, Wijdicks EF, White RD, Rabinstein AA., Cognitive outcomes of patients undergoing therapeutic hypothermia after cardiac arrest. *Neurology*. 2013 Jul 2;81(1):40-5. doi: 10.1212/WNL.0b013e318297ee7e. Epub 2013 May 17. PMID: 23685933
 28. Shokouhi S, Claassen DO, Kang H, Ding Z, Rogers B, Mishra A, Riddle WR; Alzheimer's Disease Neuroimaging Initiative. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. *J Nucl Med*. 2013 Sep;54(9):1564-9. doi: 10.2967/jnumed.112.116137. Epub 2013 Jul 17. PMID: 23864720
 29. Kleinfeld, K, Jones P, Riebau, D, Beck A, Paueksakon, P, Abel TW, Claassen DO. Vascular complications of fungal meningitis attributed to contaminated methylprednisolone injections. *JAMA Neurol*. 2013 Jul 22. doi: 10.1001/jamaneurol.2013.3586. PMID: 23877880
 30. Isaacs D, Olmez I, Claassen DO No Black and White Matter: Adult-Onset Adrenoleukodystrophy Presenting After Chemotherapy. *Neurol Clin Pract* April 2014 vol. 4 no. 2 168-170
 31. Claassen DO, van den Wildenberg WP, Harrison MB, van Wouwe NC, Kanoff K, Neimat JS, Wylie SA. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. *Pharmacol Biochem Behav*. 2015 Feb;129:19-25. doi: 10.1016/j.pbb.2014.11.017. Epub 2014 Nov 29. PMID: 25459105
 32. Shokouhi S, Rogers BP, Kang H, Ding Z, Claassen DO, Mckay JW, Riddle WR; Alzheimer's Disease Neuroimaging Initiative. Modeling clustered activity increase in amyloid-beta positron emission tomographic images with statistical descriptors. *Clin Interv Aging*. 2015 Apr 20;10:759-70. doi: 10.2147/CIA.S82128. eCollection 2015. PMID: 25945042
 33. Tolleson CM, Dobolyi DG, Roman OC, Kanoff K, Barton S, Wylie SA, Kubovy M, Claassen DO. Dysrhythmia of timed movements in Parkinson's disease and freezing of gait. *Brain Res*. 2015 Oct 22;1624:222-31. doi: 10.1016/j.brainres.2015.07.041. Epub 2015 Aug 1. PMID: 26241766
 34. Bissett PG, Logan GD, van Wouwe NC, Tolleson CM, Phibbs FT, Claassen DO, Wylie SA. Generalized motor inhibitory deficit in Parkinson's disease patients who freeze. *J Neural Transm (Vienna)*. 2015 Dec;122(12):1693-701. doi: 10.1007/s00702-015-1454-9. Epub 2015 Sep 9. PMID: 26354102
 35. van Wouwe NC, van den Wildenberg WP, Ridderinkhof KR, Claassen DO, Neimat JS, Wylie SA. Easy to learn, hard to suppress: The impact of learned stimulus-outcome associations on subsequent action control. *Brain Cogn*. 2015 Dec;101:17-34. doi: 10.1016/j.bandc.2015.10.007. Epub 2015 Nov 8. PMID: 26554843

36. van Wouwe NC, Kanoff KE, Claassen DO, Richard Ridderinkhof K, Hedera P, Harrison MB, Wylie SA. The Allure of High-Risk Rewards in Huntington's disease. *J Int Neuropsychol Soc.* 2016 Apr;22(4):426-35. doi: 10.1017/S1355617715001241. Epub 2015 Dec 28. PMID: 26708084
37. Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer's Disease Neuroimaging Initiative. Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. *Alzheimers Res Ther.* 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3. PMID: 26768154
38. van Wouwe NC, Kanoff KE, Claassen DO, Spears CA, Neimat J, van den Wildenberg WP, Wylie SA. Dissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease. *J Cogn Neurosci.* 2016 May;28(5):710-23. doi: 10.1162/jocn_a_00930. Epub 2016 Feb 2. PMID: 26836515
39. Plassard AJ, Harrigan RL, Newton AT, Rane S, Pallavaram S, D'Haese PF, Dawant BM, Claassen DO, Landman BA. On the Fallacy of Quantitative Segmentation for T1-Weighted MRI. *Proc SPIE Int Soc Opt Eng.* 2016 Feb 27;9784. pii: 978416. Epub 2016 Mar 21. PMID: 27127328
40. Plassard AJ, Yang Z, Prince JL, Claassen DO, Landman BA. Improving Cerebellar Segmentation with Statistical Fusion. *Proc SPIE Int Soc Opt Eng.* 2016 Feb 27;9784. pii: 97842R. Epub 2016 Mar 21. PMID: 27127334
41. Herb JN, Rane S, Isaacs DA, Van Wouwe N, Roman OC, Landman BA, Dawant BM, Hedera P, Zald DH, Neimat JS, Wylie SA, Donahue MJ, Claassen DO. Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction. *J Parkinsons Dis.* 2016 May 5;6(2):441-51. doi: 10.3233/JPD-150753. PMID: 27164041
42. Wylie SA*, Claassen DO*, Kanoff KE, van Wouwe NC, van den Wildenberg WP. Stopping Manual and Vocal Actions in Tourette's Syndrome. *J Neuropsychiatry Clin Neurosci.* 2016 Jun 3:appineuropsych15110387. [Epub ahead of print] PMID: 27255852 *authors contributed equally to this manuscript.
43. Claassen DO, Dobolyi DG, Isaacs DA, Roman OC, Herb J, Wylie SA, Neimat JS, Donahue MJ, Hedera P, Zald DH, Landman BA, Bowman AB, Dawant BM, Rane S. Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson's Disease. *Aging Dis.* 2016 May 27;7(3):220-9. doi: 10.14336/AD.2015.1110. eCollection 2016 May. PMID: 27330836
44. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinell S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, et al. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. *JAMA.* 2016 Jul 5;316(1):40-50. doi: 10.1001/jama. 016.8655. PMID: 27380342
45. Slagter HA, van Wouwe NC, Kanoff K, Grasman RP, Claassen DO, van den Wildenberg WP, Wylie SA. Dopamine and temporal attention: An attentional blink study in Parkinson's disease patients on and off medication. *Neuropsychologia.* 2016 Sep 6;91:407-414. doi:10.1016/j.neuropsychologia.2016.09.006. [Epub ahead of print] PMID: 27613667

46. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. *J Clin Mov Disord*. 2017 Mar 1;4:3. doi: 10.1186/s40734-017-0051-5. eCollection 2017. PMID: 28265459
47. Claassen DO, Stark AJ, Spears CA, Petersen KJ, van Wouwe NC, Kessler RM, Zald DH, Donahue MJ. Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors. *Mov Disord*. 2017 Nov;32(11):1574-1583. doi: 10.1002/mds.27047. Epub 2017 Jun 19. PMID: 28627133
48. Isaacs D, Claassen DO, Bowman AB, Hedera P. Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations. *Brain Sci*. 2017 Jun 24;7(7). pii: E71. doi: 10.3390/brainsci7070071. PMID: 28672806
49. Kremens D, Lew M, Claassen DO, Goodman BP. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease. *Clin Auton Res*. 2017 Jul;27(Suppl 1):29-31. doi: 10.1007/s10286-017-0434-6. Epub 2017 Jul 3. PMID: 28674867
50. Goodman BP, Claassen DO, Mehdiraz A. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. *Clin Auton Res*. 2017 Jul;27(Suppl 1):17-19. doi: 10.1007/s10286-017-0431-9. Epub 2017 Jun 19. PMID: 28631223
51. Claassen DO, Lew M. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. *Clin Auton Res*. 2017 Jul;27(Suppl 1):13-14. doi: 10.1007/s10286-017-0429-3. Epub 2017 Jun 19. PMID: 28631224
52. Vernino S, Claassen DO. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus. *Clin Auton Res*. 2017 Jul;27(Suppl 1):33-34. doi: 10.1007/s10286-017-0435-5. Epub 2017 Jul 3. PMID: 28674868
53. Van Wouwe NC, Claassen DO, Neimat JS, Kanoff KE, Wylie SA. Dopamine Selectively Modulates the Outcome of Learning Unnatural Action-Valence Associations. *J Cogn Neurosci*. 2017 May;29(5):816-826. doi: 10.1162/jocn_a_01099. Epub 2017 Jan 27. PMID: 28129053
54. Claassen DO, McDonell KE, Donahue M, Rawal S, Wylie SA, Neimat JS, Kang H, Hedera P, Zald D, Landman B, Dawant B, Rane S. Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. *Brain Behav*. 2016 Oct 6;6(12):e00573. doi: 10.1002/brb3.573. eCollection 2016 Dec. PMID: 28031997
55. Plassard AJ, D'Haese PF, Pallavaram S, Newton AT, Claassen DO, Dawant BM, Landman BA. Multi-Modal and Targeted Imaging Improves Automated Mid-Brain Segmentation. *Proc SPIE Int Soc Opt Eng*. 2017 Feb 11;10133. pii: 101330J. doi: 10.1117/12.2254428. Epub 2017 Feb 24. PMID: 28781412
56. Trujillo P, Summers PE, Smith AK, Smith SA, Mainardi LT, Cerutti S, Claassen DO, Costa A. Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches. *Neuroradiology*. 2017 Dec;59(12):1251-1263. doi: 10.1007/s00234-017-1911-2. Epub 2017 Oct 6. PMID: 28986653
57. Petersen K, Van Wouwe N, Stark A, Lin YC, Kang H, Trujillo-Diaz P, Kessler R, Zald D, Donahue MJ, Claassen DO. Ventral striatal network connectivity reflects reward learning and behavior in

- patients with Parkinson's disease. *Hum Brain Mapp.* 2018 Jan;39(1):509-521. doi: 10.1002/hbm.23860. Epub 2017 Oct 31. PMID: 29086460
58. Dang LC, Samanez-Larkin GR, Smith CT, Castrellon JJ, Perkins SF, Cowan RL, Claassen DO, Zald DH. FTO affects food cravings and interacts with age to influence age-related decline in food cravings. *Physiol Behav.* 2017 Dec 9. pii: S0031-9384(17)30435-3. doi: 10.1016/j.physbeh.2017.12.013. PMID: 29233619
59. Wylie SA, van Wouwe NC, Godfrey SG, Bissett PG, Logan GD, Kanoff KE, Claassen DO, Neimat JS, van den Wildenberg WPM. Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease. *Neuropsychologia.* 2017 Dec 19;109:262-269. doi:10.1016/j.neuropsychologia.2017.12.032. PMID: 29269306
60. Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY, Zald DH, Claassen DO. [18F]fallypride characterization of striatal and extrastriatal D_{2/3} receptors in Parkinson's disease. *Neuroimage Clin.* 2018 Feb 10;18:433-442. doi: 10.1016/j.nicl.2018.02.010. eCollection 2018. PMID:29541577.
61. Stark AJ, Smith CT, Lin YC, Petersen KJ, Trujillo P, van Wouwe NC, Kang H, Donahue MJ, Kessler RM, Zald DH, Claassen DO. Nigrostriatal and Mesolimbic D_{2/3} Receptor Expression in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors. *J Neurosci.* 2018 Mar 28;38(13):3230-3239. doi: 10.1523/JNEUROSCI.3082-17.2018. Epub 2018 Feb 26. PMID:29483278
62. Sung VW, Iyer RG, Gandhi SK, Shah-Manek B, DiBonaventura M, Abler V, Claassen DO. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States. *Curr Med Res Opin.* 2018 Apr;34(4):643-648. doi: 10.1080/03007995.2018.1435518. Epub 2018 Feb 16. PMID: 29383957
63. Roman OC, Stovall J, Claassen DO. Perseveration and Suicide in Huntington's Disease. *J Huntingtons Dis.* 2018 Mar 26. doi: 10.3233/JHD-170249. [Epub ahead of print] PMID: 29614688
64. Petersen KJ, Reid JA, Chakravorti S, Juttukonda MR, Franco G, Trujillo P, Stark AJ, Dawant BM, Donahue MJ, Claassen DO. Structural and functional connectivity of the nondecussating dentato-rubro-thalamic tract. *Neuroimage* 2018 Aug 1;176:364-371. doi: 10.1016/j.neuroimage.2018.04.074. Epub 2018 May 4 PMID: 29733955
65. McDonnell KE, van Wouwe NC, Harrison MB, Wylie SA, Claassen DO. Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease. *Brain Behav.* 2018 Jul;8(7):e01008. doi: 10.1002/brb3.1008. Epub 2018 Jun 1. PMID: 29856137
66. Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. *BMC Neurol.* 2018 Aug 25;18(1):125. doi: 10.1186/s12883-018-1129-x. PMID: 30144800
67. Rane S, Donahue MJ, Claassen DO. Amnesic mild cognitive impairment individuals with dissimilar pathologic origins show common regional vulnerability in the default mode network. *Alzheimers Dement (Amst).* 2018 Sep 20;10:717-725. doi: 10.1016/j.dadm.2018.08.004. eCollection 2018. PMID: 30511009
68. Smith CT, San Juan MD, Dang LC, Katz DT, Perkins SF, Burgess LL, Cowan RL, Manning HC,

- Nickels ML, Claassen DO, Samanez-Larkin GR, Zald DH. Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. *Transl Psychiatry*. 2018 Dec 7;8(1):269. doi: 10.1038/s41398-018-0328-y. PMID: 30531858
69. Claassen DO, Iyer RG, Shah-Manek B, DiBonaventura M, Ablner V, Sung VW. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review. 2018;7(4):345-353. doi: 10.3233/JHD-170286. PMID: 30282372
 70. Juttukonda MR, Franco G, Englot DJ, Lin YC, Petersen KJ, Trujillo P, Hedera P, Landman BA, Kang H, Donahue MJ, Konrad PE, Dawant BM, Claassen DO. White matter differences between essential tremor and Parkinson disease. *Neurology*. 2019 Jan 1;92(1):e30-e39. doi: 10.1212/WNL.0000000000006694. Epub 2018 Nov 30. PMID: 30504432
 71. Hughes S, Claassen DO, van den Wildenberg WPM, Phibbs FT, Bradley EB, Wylie SA, van Wouwe NC. Action Control Deficits in Patients With Essential Tremor. *J Int Neuropsychol Soc*. 2019 Feb;25(2):156-164. doi: 10.1017/S1355617718001054. Epub 2018 Dec 3. PMID: 30501660
 72. Trujillo P, van Wouwe NC, Lin YC, Stark AJ, Petersen KJ, Kang H, Zald DH, Donahue MJ, Claassen DO. Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease. *Cortex*. 2019 Jan 29;115:99-111. doi: 10.1016/j.cortex.2019.01.016. [Epub ahead of print] PMID: 30776736
 73. Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. *Expert Opinion on Pharmacotherapy*. 2019. 20(18): 2209-2221. doi: 10.1080/14656566.2019.1674281. Epub 2019 Oct 15. PMID: 31613641
 74. Trujillo P, Petersen KJ, Cronin MJ, Ya-Chen L, Kang H, Donahue MJ, Smith SA, Claassen DO. Quantitative magnetization transfer imaging of the locus coeruleus. *NeuroImage*. 2019 Jun 21; 200:191-198. doi: 10.1016/j.neuroimage.2019.06.049. Epub 2019 Jun 21. PMID: 31233908
 75. Gonzalex HFC, Chakravort S, Goodale SE, Gupta K, Claassen DO, Dawant B, Morgan VL, Englot DJ. Thalamic arousal network disturbances in temporal lobe epilepsy and improvement after surgery. *J Neurol Neurosurg Psychiatry*. 2019 Oct;90(10):1109-1116. doi: 10.1136/jnnp-2019-320748. Epub 2019 May 23. PMID: 31123139
 76. McDonnell KE, Shiao CA, Biaggioni I, Hartman A, Robertson D, Claassen DO. Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review. *Cogn Behav Neurol*. 2019 Sep;32(3):179-184. doi: 10.1097/WNN.000000000000198. PMID: 31517701
 77. Johnson SE, McKnight CD, Lants SK, Juttukonda MR, Fusco M, Chitale R, Donahue PC, Claassen DO, Donahue MJ. Choroid plexus perfusion and intracranial cerebrospinal fluid changes after angiogenesis. *J Cereb Blood Flow Metab*. 2019 Sep 9;271678X19872563. doi: 10.1177/0271678X19872563. [Epub ahead of print]. PMID: 31500523
 78. Diehl SK, Mefferd AS, Lin YC, Sellers J, McDonnell KE, de Riesthal M, Claassen DO. Motor speech patterns in Huntington disease. *Neurology*. 2019 Nov 26;93(22):e2042-e2052. doi: 10.1212/WNL.0000000000008541. Epub 2019 Oct 29. PMID: 31662494
 79. Sellers J, Darby RR, Farooque A, Claassen DO. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. *Drugs Aging*. 2019 Jul;36(7):647-653. doi:

10.1007/s40266-019-00655-y. PMID: 30924099

80. Bermudez Noguera C, Bao S, Petersen KJ, Lopez AM, Reid J, Plassard AJ, Zald DH, Claassen DO, Dawant BM, Landman BA. Using deep learning for a diffusion-based segmentation of the dentate nucleus and its benefits over atlas-based methods. *J Med Imaging (Bellingham)*. 2019 Oct;6(4):044007. doi: 10.1117/1.JMI.6.4.044007. Epub 2019 Dec 6. PMID: 31824980
81. Plassard AJ, Bao S, D'Haese PF, Pallavaram S, Claassen DO, Dawant BM, Landman BA. Multi-modal imaging with specialized sequences improves accuracy of the automated subcortical grey matter segmentation. *Magn Reson Imaging*. 2019 Sep;61:131-136. doi: 10.1016/j.mri.2019.05.025. Epub 2019 May 21. PMID: 31121202
82. Parvathaneni P, Bao S, Nath V, Woodward ND, Claassen DO, Cascio CJ, Zald DH, Huo Y, Landman BA, Lyu I. Cortical Surface Parcellation Using Spherical Convolutional Neural Networks. *Med Image Comput Comput Assist Interv*. 2019 Oct;11766:501-509. doi: 10.1007/978-3-030-32248-9_56. Epub 2019 Oct 10. PMID: 31803864
83. Aumann MA, Stark AJ, Hughes SB, Lin YC, Kang H, Bradley E, Zald DH, Claassen DO. Self-reported rates of impulsivity in Parkinson's Disease. *Annals of Clinical and Translational Neurology*. 2020 Mar; 7(4): 437-448. doi: 10.1002/acn3.51016
84. Lopez AM, Trujillo P, Hernandez AB,, Lin YC, Kang H, Landman BA, Englot DJ, Dawant BM, Konrad PE, Claassen DO. Structural Correlates of the Sensorimotor Cerebellum in Parkinson's Disease and Essential Tremor. *Movement Disorders*. 2020 Jul; 35(7): 1181-1188. doi: 10.1002/mds.28044 PMID: 32343870
85. Ciriegio AE, Pfalser AC, Hale L, McDonell KE, Claassen DO, Compas BE. Investigating the Interplay of Working Memory, Affective Symptoms, and Coping with Stress in Offspring of Parents with Huntington's Disease. *Neuropsychology*. In press.
86. Carlozzi NE, Boileau NR, Roberts A, Dayalu P, Hanifan DL, Miner JA, Claassen D, Provost EM. Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks. *Quality of Life Research*; in press: DOI: 10.1007/s11136-020-02608-0 Epub 2020 Aug. PMID: 32839864

Invited Reviews/Editorials/ Book Chapters:

1. Claassen DO, Kutscher SJ Sleep disturbances in Parkinson's disease patients and management options. *Nature and Science of Sleep*. 2011 Dec;3:125-133. *Nat Sci Sleep*. 2011 Dec 1;3:125-33. doi: 10.2147/NSS.S18897. PMID: 23616723.
2. Claassen DO: The Netter Collection of Medical Illustrations, 2nd Edition. Frank H. Netter, MD. Editors: H. Royden Jones, Ted M. Burns, Michael J. Aminoff, Scott L. Pomeroy. 2013 Published by Saunders, an imprint of Elsevier, INC. Section 2: 2.1-2.31.
3. Claassen DO, Wylie SA. Trends and issues in characterizing early cognitive changes in Parkinson's disease. *Curr Neurol Neurosci Rep*. 2012 Dec;12(6):695-702. doi: 10.1007/s11910-012-0312-5. PMID: 22949166
4. Claassen DO, Kanoff KE, Wylie SA. Dopamine Agonists and Impulse Control Disorders in Parkinson's Disease. *US Neurology Review* 2013;9(1)

5. Kutscher SJ, Farshidpanah S, Claassen DO. Sleep Dysfunction and It's Management in Parkinson's Disease. *Curr Treat Options Neurol*. 2014 Aug;16(8)
6. Shokouhi S, Claassen DO, Riddle W. Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. *J Alzheimers Dis Parkinsonism*. 2014 Apr;4(2). pii: 143. PMID: 25343059
7. McDonnell KE, Shibao CA, Claassen DO. Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease. *Curr Neurol Neurosci Rep*. 2015 Dec;15(12):78. doi: 10.1007/s11910-015-0599-0. PMID: 26486792
8. Lopez AM, Weintraub D, Claassen DO. Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. *Semin Neurol*. 2017 Apr;37(2):186-192. doi: 10.1055/s-0037-1601887. Epub 2017 May 16. PMID: 28511259
9. Samson M, Claassen DO. Neurodegeneration and the Cerebellum. *Neurodegener Dis*. 2017;17(4-5):155-165. doi: 10.1159/000460818. Epub 2017 May 3. PMID: 28463835
10. Weintraub D, Claassen DO. Impulse Control and Related Disorders in Parkinson's Disease. *Int Rev Neurobiol*. 2017;133:679-717. doi: 10.1016/bs.irm.2017.04.006. Epub 2017 Jun 1. PMID: 28802938
11. Stark AJ, Claassen DO. Positron emission tomography in Parkinson's disease: insights into impulsivity. *Int Rev Psychiatry*. 2017 Dec;29(6):618-627. doi: 10.1080/09540261.2017.1398139. Epub 2017 Dec 5. PMID: 29206483
12. Claassen DO, Torres-Russotto D. CSF microRNA in patients with Huntington disease. *Neurology*. 2017 Dec 27. pii: 10.1212/WNL.0000000000004871. doi: 10.1212/WNL.0000000000004871. [Epub ahead of print] PMID: 29282335

Abstracts/Presentations:

1. Hill WD, Hess DC, Claassen DO. Erythropoietin Treatment Started Two Days After Middle Cerebral Artery Ligation Prevents Loss of Behavioral Function. *International Stroke Conference New Orleans, LA., 2005*
2. Claassen DO, Batsis JA, Orenstein R. The First Reported Case of Non- Fatal, Non-operative Proteus Mirabilis Native Valve Endocarditis. *Minnesota ACP, Minneapolis, MN. March 2005*
3. Claassen DO, Zubkov AY, Manno EM , Wijdicks EFM, Rabinstein AA Higher INR does not predict mortality in Warfarin-related Intracerebral Hemorrhage, *American Academy of Neurology, Boston, MA. April 2007*
4. *Claassen DO, Zubkov AY, Manno EM , Wijdicks EFM, Rabinstein AA., Reinitiating Anticoagulation after Warfarin-Associated Hemorrhage, *American Neurological Association, Washington, DC. October 2007*
5. Claassen DO, Walting PJ, Tan KM, Pittock S, So E, Elvis and Epilepsy; a case of musicogenic epilepsy treated with music, *American Epilepsy Society, Philadelphia, PA. December 2007.*
6. Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA., Overlapping Features of Dementia with Lewy Bodies and Frontotemporal Dementia associated with Pathological Frontotemporal Lobar Degeneration with Motor Neuron Disease, *American Academy of Neurology, Chicago, IL. April 2008*

7. Claassen DO, Burnett MS, Huston J, Maraganore DJ, Secondary Parkinsonism and a Distorted Midbrain, International Movement Disorders Society, Chicago, IL. June 2008.
8. Claassen DO, Kazemi NJ, Josephs KA., SPECT patterns of cerebral perfusion in 3 clinical behavioral variants of frontotemporal dementia, Alzheimer's Imaging Consortium 2008, Chicago, IL. July 2008
9. Claassen DO, Kazemi NJ, Josephs KA., Patterns of cerebral perfusion in 3 clinical behavioral variants of frontotemporal dementia, 11th International Conference on Alzheimer's Disease, Chicago, IL. July 2008
10. Claassen DO, Zubkov AY, Manno EM , Wijdicks EFM, Rabinstein AA, A Divergence of Opinion: Restarting Warfarin after Warfarin Associated Intracerebral Hemorrhage, Neurocritical Care Conference, Miami, FL. October 2008
11. Claassen DO, Josephs KA, Ahlskog JE, Smith GE, Silber MH, Tippmann-Peikert M, Boeve BF., REM sleep behavior disorder may precede PD, DLB or MSA by up to half a century, American Academy of Neurology, Seattle, WA. April 2009
12. *Claassen DO, Wijdicks EFM, Manno EM, Boeve BF, Rabinstein AA., Cognitive outcomes in patients surviving cardiac resuscitation, American Academy of Neurology, Seattle, WA. April 2009
13. Claassen DO, Josephs KA, Peller PJ. Focal Primary Motor Cortex Hypometabolism Identified in Patients with Primary Lateral Sclerosis, American Neurological Association, Baltimore, MD. October 11-14, 2009
14. Claassen DO, Josephs KA, Peller PJ. Clinical Correlates of Asymmetric Posterior Frontal and Parietal Glucose Hypometabolism, American Neurological Association, Baltimore, MD. October 11-14, 2009
15. *Claassen DO, Josephs KA, Peller PJ. Assessing Non-cortical Glucose Metabolism in Corticobasal Syndrome. World Federation of Neurology, Miami FL. December 2009
16. Claassen DO, Josephs KA, Peller PJ. Clinical Correlations of Asymmetric Temporal and Parietal Lobe Glucose Hypometabolism. American Academy of Neurology, Toronto ON. April 2010
17. *Fugate JE, Claassen DO, Kozak OS, Cloft H, Kallmes DF, Rabinstein AA. Presentations and Clinical Associations of Posterior Reversible Encephalopathy Syndrome, American Academy of Neurology , Toronto ON. April 2010
18. Fugate JE, Wijdicks EFM, Claassen DO, Rabinstein AA. Neuron specific enolase as a predictor in therapeutic hypothermia after cardiac arrest. American Academy of Neurology, Toronto ON. April 2010
19. Wijdicks EFM Fugate JE, Claassen DO, Rabinstein AA .The FOUR Score is a Predictor of Outcome in Comatose Patients after Cardiac Arrest. American Academy of Neurology, Toronto ON. April 2010
20. *Claassen DO, Lowe VJ, Peller PJ , Petersen RC, Josephs KA, , Cerebral amyloid deposition can distinguish Multiple Systems Atrophy from Dementia with Lewy Bodies, American Neurological Association, San Francisco, CA. September 2010
21. Claassen DO, Wooten GF, Harrison MB, Wylie SA. Risk taking is altered in Parkinson Disease by Dopamine Agonists, American Neurological Association, San Francisco, CA. September 2010
22. *Claassen DO, Wooten GF, Wylie SA. Increased Risk Behavior in Impulse Control Disorders, International Neuropsychological Society, Boston, MA. February 2010
23. Claassen DO, Wooten GF, Harrison MB, Wylie SA, Heightened Reward Learning in Parkinson Disease Patients with Impulse Control Disorder Symptoms, American Academy of Neurology, Honolulu HI. April 2010

24. *Claassen, DO, Wooten GF, Wylie SA, Patients with Impulsive Compulsive Behavior can adjust risk taking in response to negative consequences, Parkinson's Study Group, Irving TX, May 2010.
25. *Claassen, DO, van den Wildenberg WPM, Wooten GF, Wylie SA Motor impulsivity in Parkinson Disease patients with the Postural Instability with Gait Difficulties Subtype MDS 16th International Congress of Parkinson's Disease and Movement Disorders, Dublin Ireland. June 2012
26. Claassen DO, Kanoff K, van den Wildenberg WPM, Harrison MB, Wooten GF, Wylie SA, Proficient Inhibitory Control in Patients with Parkinson Disease and Impulse Control Disorder Impulse Control Disorders in Parkinson's Disease, Boston, MA. October, 2012.
27. *Donahue MJ, Clemmons R, Andal R, Singer R, Brown D, Anderson M, Claassen DO, Connors J, Hermann L, Jordan L, Kirshner H, Mocco J, Moore R, O'Duffy A, Riebau D, Sills A, Strother M, Noninvasive Multi-echo Vessel-Encoded Arterial Spin Labeling Reactivity for More Comprehensive Quantification of Hemodynamic Compensation: Development and Clinical Implementation in 50 Patients with Cerebrovascular Disease ISMRM Annual Meeting Salt Lake City, UT. April, 2013
28. *Moore S, Fugate JE, Knopman DS, Claassen DO, Wijdicks EFM, White RD, Rabinstein AA Cognitive Outcomes of Patients Undergoing Therapeutic Hypothermia after Out-of-Hospital Cardiac Arrest, American Academy of Neurology, San Diego CA. March 2013
29. Claassen DO, Kanoff K, van den Wildenberg WPM, Harrison MB, Wooten GF, Wylie SA, Proficient Inhibitory Control in Patients with Parkinson Disease and Impulse Control Disorder, American Academy of Neurology, San Diego CA. March 2013
30. *Claassen, DO, Nelleke C. van Wouwe, G. Fred Wooten, Madaline Harrison, Scott A. Wylie. Taq1A polymorphism improves Dopamine Agonist therapeutic response in Parkinson's Disease, World Congress of Parkinson Disease, Montreal Canada. October 2013
31. *Jones CR, Claassen DO, Yu M, Spies J, Malone T, Dirnberger G, Parkinson M, Giunti P, Kubovy M and Jahanshahi M (2013). The impact of cerebellar and basal ganglia dysfunction on the accuracy and variability of motor timing. Front. Hum. Neurosci. 14th Rhythm Production and Perception Workshop Birmingham 11th - 13th September 2013. doi: 10.3389/conf.fnhum.2013.212.00039
32. van Wouwe NC, Wylie SA, Kanoff K, Harrison M, Claassen DO. Differential Adjustments to High Risk Reward Outcomes in Huntington's disease. Huntington Disease Study Group, Charlotte NC. November 2013
33. Kanoff, K., Van den Wildenberg, W., Claassen, DO. Wylie, S. Tourette's syndrome impairs inhibition of voluntarily initiated manual and vocal responses. 43rd annual meeting of the Society for Neuroscience, San Diego, CA. November, 2013
34. Van Wouwe, NC., van den Wildenberg, W.P., Claassen, DO., Kanoff, K., Bashore, TR. Wylie, SA., Speed pressure in conflict situations impedes inhibitory action control in Parkinson's Disease. 43rd annual meeting of the Society for Neuroscience, San Diego, CA. November, 2013
35. *Claassen, DO. Participating in Parkinson's Disease Research The Michael J. Fox Foundation, Southeast Clinical Trials Fair, Chattanooga TN. February 2014.
36. *Claassen, DO. Huntington's Disease: Therapy for Chorea in the Long Term Care Setting. American Medical Directors Association, (AMDA) Nashville, TN. February 2014
37. Shokouhi, S., Claassen, DO. Weighted two-point correlation functions in A β -PET analysis. SNMMI Annual Meeting, St. Louis, MO. June 7, 2014

38. Issacs D, Herb J, Claassen DO. Parkinson's Disease Motor Phenotype Predicts Cognitive Performance. American Academy of Neurology, Philadelphia PA. April 2014
39. Claassen, DO., Donahue, M., Rane, S. CSF alpha synuclein levels modulate BOLD connectivity of executive control network regions in Parkinson's disease. ISMRM 23rd Annual Meeting & Exhibition in Toronto, Ontario, Canada. 2015.
40. *Rane S, Landman B, Dawant B, Bowman A, Zald D, Donahue M, and Claassen, DO. "Parkinson's patients show distinct patterns of atrophy in the first and second decade of disease," ADPD, Nice, France, March 2015
41. Zald, D. Claassen, DO. Cortical Distinctions in Parkinson Disease patients with Predominant Gait Dysfunction. American Academy of Neurology 67th Annual Meeting, April, 2015, Washington, DC
42. *Moro, K, Neimat J, Wylie SA, Claassen, DO, Self-ratings of impulsive and compulsive behaviors decrease in Parkinson's patients following deep brain stimulation of the subthalamic nucleus. American Academy of Neurology 67th Annual Meeting, April 2015, Washington, DC
43. Rane, S, Donahue M, Claassen, DO. Functional connectivity in Parkinson's disease is differentially impacted by alpha-synuclein and amyloid. Movement Disorder Society, 19th International Congress, June 2015, San Diego CA
44. * Plassard, AJ, Harrigan, RL, Newton AT, Rane SD, Pallavaram S, D'Haese PF, Dawant BM, Claassen, DO, Landman, BA "On the Fallacy of Quantitative Segmentation for T1-Weighted MRI." In Proceedings of the SPIE Medical Imaging Conference. San Diego, California, February 2016. Oral presentation.
45. Plassard, AJ Yang, Z, Rane, SD, Prince JL, Claassen, DO, Landman BA, "Improving Cerebellar Segmentation with Statistical Fusion. In Proceedings of the SPIE Medical Imaging Conference. February 2016, San Diego, CA.
46. McDonell KE, Shiba CA, Biaggioni I, Robertson D, Claassen DO. Cognitive and Behavioral Side Effects in Patients Treated with Droxidopa for Neurogenic Orthostatic Hypotension. American Academy of Neurology, Vancouver, BC. April 2016.
47. Sung V, Claassen DO, Edmondson MC et al. Comparable neuropsychiatric safety observed with deutetrabenazine treatment and placebo with Huntington disease (First-HD). American Psychiatric Association 169th Annual Meeting, Atlanta, GA, May, 2016
48. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June 2016
49. Claassen DO, Donga P, Rajagopalan S, De Boer LM, Carroll B, Gandhi S., Epidemiology and economic burden of falls and fractures in patients with Huntington's disease. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June 2016
50. Claassen DO, Oakes D, Stamler D, Sung V, Testa CM, Frank S, on behalf of the First-HD HSG Investigators. Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June 2016
51. Roman O, Stovall J, Claassen DO. Suicide attempts and Huntington's disease: Perseveration, not just impulsivity. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June 2016
52. S.A. Frank, D.O. Claassen, S. Janicki, D. Oakes, D. Stamler, V. Sung, C. Vaughn, C.M. Testa, On

- behalf of First-HD HSG Investigators. Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June, 2016.
53. Testa CM, Claassen DO, Oakes D, Stamler D, Sung V, Frank S, on behalf of the First-HD HSG Investigators. Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June, 2016
 54. McDonnell K, Biaggioni I, Shibao C, Claassen DO. Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June 2016
 55. Borellini L, Franco G, Trujillo P, Summers P, Di Fonzo A, Claassen DO, Costa A. Neuromelanin-MRI of substantial nigra subregions in Parkinson's disease. Movement Disorders Society, 20th Annual Conference, Berlin, Germany. June 2016
 56. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D Comparative Effectiveness of Deutetrabenazine and Tetrabenazine in the First-HD and TETRA-HD Trials. Milton Wexler Symposium of Life Meeting, Hereditary Disease Foundation, August 2016.
 57. Claassen DO, Iyer R, Dimbil M, Giron A, De Boer LM, Gandhi S, Hoffman KB. Post-Marketing Adverse Events Associated with Tetrabenazine: Findings Using the FDA Adverse Event Reporting System. European Huntington Disease Network Plenary Meeting, The Hague, Netherlands, September 2016
 58. Claassen DO, Carroll B, De Boer LM, Iyer R, Ayyagari R, Mu F, Gandhi S, Stamler D . Number needed to Harm (NNH) analysis of Deutetrabenazine and Tetrabenazine from two pivotal trials: FIRST-HD and TETRA-HD 9th European Huntington Disease Network Plenary Meeting, The Hague, Netherlands, September 2016
 59. Petersen K, Claassen DO, Donahue M. Functional Connectivity Mapping Using 3D GRASE Arterial Spin Labeling MRI. 25th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM). Honolulu, USA, April 2017
 60. *Claassen DO, Stark A, Spears C, Petersen K, Wylie S, van Wouwe N, Kessler R, Zald D, Donahue M. Pharmacological Arterial Spin Labeling Reveals Distinct Mesocorticolimbic Blood Flow in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors. 25th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM). Honolulu, USA, April 2017
 61. Trujillo P, Summers P, Smith A, Smith S, Costa A, Claassen DO. Quantitative Magnetization Transfer Imaging of the Substantia Nigra in Parkinson's Disease. 25th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM). Honolulu, USA, April 2017
 62. Petersen K, Stark A, Kessler R, Van Wouwe N, Donahue M, Claassen DO. Ventral Striatal Blood Flow and Network Synchrony Reflect Reward Learning and Behavior in Patients with Parkinson's Disease. American Neurological Association, San Diego, USA, 2017.
 63. Diehl, S.K., Mefferd, A., de Riesthal, M., Ya-Chen, Lin, Bradley, K., Claassen, DO. Speech perceptual characteristics of individuals with dysarthria secondary to Huntington's disease. Paper presented at the American Speech Language Hearing Association Annual National Convention, Los Angeles, CA. 2017

64. Petersen K, Stark A, Kessler R, Van Wouwe N, Donahue M, Claassen DO. Multimodal fMRI investigation of reward-driven behaviors in Parkinson's disease. Society for Neuroscience, Washington, DC, USA, November 2017
65. Stark A, Petersen K, Trujillo P, Kessler R, Zald DH, Claassen DO. Striatal and extrastriatal D2-like receptor expression in Parkinson's disease patients with compulsive reward-driven behaviors. Society for Neuroscience, Washington, DC, USA, November 2017
66. Trujillo P, Stark AJ, Petersen K, Kessler R, Zald DH, Claassen DO. Mesolimbic D2-like receptor expression in patients with Parkinson's disease. Society for Neuroscience, Washington, DC, USA, November 2017
67. Diehl, S.K., Mefferd, A., de Riesthal, M., Ya-Chen, Bradley, K., Claassen, DO . Speech perceptual characteristics of individuals with dysarthria secondary to Huntington's disease. Paper presented at the Bill Wilkerson Center for Otolaryngology and Communication Sciences Combined Poster Session, Nashville, TN 2018 . *Second place award for poster presentation.
68. Diehl, S.K., Mefferd, A., Claassen, DO, Ya-Chen, L., & de Riesthal, M. Deviant patterns of speech in Huntington's disease. Paper submitted for presentation at the American Speech Language Hearing Association Annual National Convention, Boston, MA. 2018
69. Diehl, S.K., Duff, M., Claassen, DO, DeWall, Z., & de Riesthal, M. Patient and caregiver reported discourse deficits in Huntington's disease. American Speech Language Hearing Association Annual National Convention, Boston, MA. 2018.
70. Kukreti N, Trujillo-Diaz P, Van Wouwe N, Claassen D. Patient Perceptions of Dopaminergic Therapy Withdrawal in Parkinson's disease. MDS International Congress, Hong Kong, 2018.
71. Trujillo P, Petersen KJ, Smith SA, Claassen DO. Quantitative Magnetization Transfer of the Human Locus Coeruleus. Proc Intl Soc Mag Reson Med, 2019.
72. Lopez A, Claassen D, Trujillo Diaz P. Cerebellar Structure in Patients with Parkinson's Disease and Essential Tremor. American Academy of Neurology, 2019.
73. Lopez A, Claassen DO, Trujillo P. Cerebellar Structure in Patients with Parkinson's Disease and Essential Tremor. American Academy of Neurology. Philadelphia, PA. 2019.
74. Roman, O, Trujillo-Diaz, P, Hay, K, Biaggioni, I, Shibao, C, Claassen D. Neuromelanin-MRI in patients with Pure Autonomic Failure. MDS International Congress. Nice, France, 2019.
75. Hay, KR, McDonell, KM, Trujillo, P, Donahue, M, van Wouwe, N, Claassen DO. Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson's disease patients. MDS International Congress. Nice, France. 2019
76. *Hay, KR, McDonell, KM, Trujillo P, Shibao, C, Paranjape, S, Roman, O, Claassen DO. Autonomic Changes in Parkinson's Disease Patient treated with L-threo-3,4-dihydroxyphenylserine and high dose carbidopa therapy. American Autonomic Society. Clear Water Beach, FL. 2019.

* Platform Presentation